Brind.

Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.

7 reports, 1 independent Updated Jul 28
Gone quiet
Reports
7
Developments
2
Repetition
86%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Sub-event
  2. Syndax uses LinkedIn for company communication regarding its FDA-approved pipeline.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmac
  • GlobeNewswireSyndax Announces Participation in September Investor Conferences NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advanc
  • GlobeNewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmace
  • GlobeNewswireSyndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a co
  • Unknown outlet
2 more outlets ran the same wire story